Dyadic International, Inc., a US-based biotechnology firm specialising in advanced microbial platforms for protein development and bioproduction, has announced a significant advancement in its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm, Life Science Research Israel (LSRI).

The collaboration aims to target emerging diseases by leveraging Dyadic's expertise in microbial platforms for protein bioproduction and IIBR's capabilities in antibodies and antigens discovery.

This partnership seeks to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. By combining Dyadic's flexible scale protein bioproduction technologies with IIBR's antibodies and antigens discovery capabilities, the goal is to create effective treatments and vaccines to combat global health challenges. The intention is to eventually commercialise these solutions through collaborative out-licensing initiatives, although the current framework is non-binding and subject to the negotiation of a binding agreement.

The joint effort will involve enhancing Dyadic's C1 cell lines using proprietary gene sequences from IIBR to improve the biomanufacturing of recombinant vaccines and neutralising agents, including targeted antigens and monoclonal antibodies. The focus is on addressing emerging diseases through global commercial out-licensing initiatives to enhance access and affordability of vaccines and antibodies.